

1. 1991 . 130.
2. 10
3. , 1992. . 225-231.
4. *Anesthesia for Obstetrics* / edited by Sol M. Shnider, Gershon Levinson. 3 ed. Baltimor. 1993. p. 397-407.
5. Brown MA, Wang J, Whitworth JA. The rennin-angiotensin-aldosterone system in pre-eclampsia. *Clin-Exp-Hypertens*. 1997 Jul-Aug; 19(5-6): 713-26.
6. James M. The role of the anaesthetist in management of pre-eclampsia. *World anaesthesia*. 1998 9 p. 17-22.
7. Kirshon B, Lee W, Mauer MB, Cotton DB. Effects of low dose dopamine therapy in the oliguric patient with pre-eclampsia. *American J of Obstet and Gynecol* 1985; 159: 604-7.
8. Khatum S, Kanayama N, Hossain B, el-Maradny E, Kobayashi T, Jahan S, Bhuiyan A, Terao T. Increased concentration of plasma epinephrine and norepinephrine in patients with eclampsia. *Eur-J-Obstet_Gynecol-Reprod-Biol*. 1997 Jul; 74(1): 103-9.
9. Langer B, Grima M, Coquard C, Bader AM, Schlaeder G, Imbs JL. Plasma active rennin, angiotensin I, angiotensin II during pregnancy and in preeclampsia. *Obstet-Gynecol*. 1998 Feb 91(2): 196-202.
10. Manyonda IT, Slater DM, Fenske C, Hole D, Choy MY, Wilson C. A role for noradrenaline in pre-eclampsia: towards a unifying hypothesis for the pathophysiology. *Br-J-Obstet-Gynec*. 1998 Jun; 105(6): 641-8.

S. Brechin, G. Stephen, L. Allerton

Faculty of Sexual and Reproductive
Healthcare Clinical Guidance Intrauterine
Contraception, 2007

()
(),
().
(2007)

-Good Practice Points	

(United Kingdom Medical Eligibility Criteria)

. 2.

, (),

(World Health Organization Medical Eligibility Criteria for Contraceptive Use, WHO MECS) [5],

(. 3).

1.

(GPP).

1	
2	
3	
4	

9].

() [10]. , - () -
 25 , 25 , - . , -
 25 , - [13]. -
 , , -
 , , -
 . FSRH () -
 , () [4]. -
 . C. trachomatis. -
gonorrhoeae , *. trachomatis, N.* -
N. gonorrhoeae , -
 . -
 -

3

1- ()	2- ()	
• 20	• 20	1- , 2-
• 4 I	• II ,	-
• -	• -	-
• , , ,	• -	(), ,
()	• -	, -
-	• -	, -
.	-	, -
, ()	• ,	(),
.	• -	, -
()	• -	.
•	• -	,
•	• -	BRCA1 (breast cancer 1)
•	-	,
•	(, ,
•	,	20

1- ()	2- ()	
<p>•</p> <p>•</p> <p>()</p> <p>•</p> <p>hCG ()</p> <p>•</p> <p>•</p> <p>()</p> <p>•</p> <p>•</p> <p>() , () , ()</p> <p>•</p> <p>•</p> <p>()</p> <p>•</p> <p>•</p>	<p>-</p> <p>•</p> <p>•</p> <p>() , ()</p> <p>•</p> <p>()</p> <p>•</p> <p>•</p> <p>()</p> <p>-</p> <p>•</p> <p>•</p> <p>() , ()</p> <p>-</p> <p>•</p> <p>•</p> <p>()</p> <p>-</p> <p>•</p> <p>•</p>	<p>•</p> <p>•</p> <p>- , -</p> <p>•</p> <p>() ()</p> <p>•</p> <p>•</p> <p>2-</p> <p>•</p> <p>, 1-</p> <p>-</p> <p>•</p> <p>:</p> <p>•</p> <p>(,</p> <p>) ,</p> <p>-</p> <p>•</p> <p>•</p> <p>(,</p> <p>)</p> <p>-</p> <p>•</p> <p>•</p>
3- () I	4- ()	
<p>•</p> <p>•</p> <p>48 4</p> <p>()</p> <p>•</p>	<p>•</p> <p>•</p> <p>hCG</p> <p>•</p> <p>•</p> <p>•</p> <p>•</p> <p>•</p> <p>•</p> <p>•</p>	<p>•</p> <p>•</p> <p>1-</p> <p>•</p> <p>•</p> <p>3-</p> <p>•</p> <p>•</p> <p>:</p> <p>•</p> <p>•</p> <p>•</p> <p>•</p> <p>•</p> <p>•</p> <p>1-</p> <p>•</p> <p>•</p> <p>4-</p> <p>•</p> <p>•</p> <p>:</p> <p>•</p>

1.

(. . .),

2.

().

3.

().

C. trachomatis
N. gonorrhoea

trachomatis (GPP).

4.

5.

().

Formulary (BNF),

(GPP).

British National

().

()

()

(>75%)
6.

5,2) [49].

2,3% (95% : 0,6-
Flexi-
380

Flexi-
380

(B).

[40].

380

— 1-2%

[4].

35

5-

7.

TCu380A

5

TCu380A TCu380S <1% <2%

().

TCu380S

TCu380S

TCu380A

[44,45].

TCu380S.

5

(95-
[]: 3,0-0,2).

12

TCu380A

5

TCu380A
Multiload Cu375 10- ; 4 —
[46, 48]. [53].

Nova-T380

TCu380S 40

Nova-T380. [2, 54].

50 , , , 0,9 1000 [61].
50 . , , , 380
, , , 45- , 7-
[4]. 13. [62].
, , , 2 1000
7 , , (B).
45 [55, 56].
, , 20
, , 3 .
[4, 59].
, ,
MultiloadCu375
380 4
8. 380 TCu380S TCu380S 380 ,
10) ,
9. TCu380S - 5 ().
[49]
, , Nova-
T380 TCu380S.
10. ().
, , 14. ,
40 , 1:20,
(B). 3
50) (15. (A).
(50),
11. ().
5- ().
12. 45
(GPP). ()
, , , ,
(), — 0-2,3 1000 , , « - » ,
[4, 58, 60]. : 0,91-1,24) [68]. 1,06; 95%

100 0,02 100 (0,3-0,5 18. 20

16.) [43, 55, 62, 71].

(A).

» ()

[74]. (65%)

3 (25%), (1%)

17. (B).

12 19. (TCu380A) (GyneFix)

— 1,6 1000 20. (3-6) 6

[80].

20

20 ()

().

50%

[43].

[71].

[100].

23.

21.

[88].

GPP).

().

95].

[94,

T u380S (TT380 Slimline and T-Safe 380A QuickLoad) [4, 40].

380².

[96].

6,5

[97, 98].

« - »

0,51; 95% : 0,3-0,8) [99].

T u380S

22.

24.

/

().

GPP).

25.

(A).

« » ().

- ;
- ;
- ;
- ;

7-

[4].

10

10 100 [101].

(,)

12 12

6

48 28.

(GPP).
29. (GPP).

26.

().

27.

(GPP).
50%

(GPP).

(

30 ,
 , 6 [100].
 (400)
 [100].
 30.
 () .
 [108].
 () /
 31.
 (GPP).
 FSRH,
 ()
 ;
 gonorrhoeae. *trachomatis* N.
 no-touch.
 32.
 () .
 33.
 ()

(GPP).

34.

().

(3-6)

[7,8].

4

-	-
-	7
	40 , 50 , 7 , 50
	45 , 5 (
),

7

(

)

;

(1)

.

 « - »

[3]. -
 , -
 Candida spp. ,
 70- ,
 SENIC (Study of
 Efficacy of Nosocomial Infection Control), -
 -
 (42%) (24%)
 [3]. -
 11%.
 90- -
 17%, 1995 15-
 30%, -
 - 46,9% [1,
 4]. -
 , -
 , -
 1995 , -
 4,5 . -
 40
 [9].
 90% 88 [5]. -
 5-6 100
 [2]. [5]. -
 , -
 , -
 , -
 80% -
